ZVRA Q3 2022 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+46.3% YoY

Gross Profit

$3M95.1% margin

Operating Income

-$7M-230.5% margin

Net Income

-$7M-230.2% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+121.1%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$911,000

Balance Sheet

Total Assets

$120M

Total Liabilities

$26M

Stockholders' Equity

$94M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+46.3%
Gross Profit	$3M	$2M	+39.1%
Operating Income	-$7M	-$2M	-198.2%
Net Income	-$7M	-$2M	-276.1%